AVXS AveXis Inc.

94.41
+2.81  (3%)
Previous Close 91.60
Open 91.32
Price To book 6.83
Market Cap 3014081357
Shares 31,925,446
Volume 273,207
Short Ratio 12.39
Av. Daily Volume 407,007

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated 3Q 2017.
AVXS-101
Spinal muscular atrophy (SMA)
Initiate pivotal trial in 3Q 2017 - potency assay data due to FDA in August, 2017.
AVXS-101
Spinal muscular atrophy (SMA) Type 1

SEC Filings

  1. CT ORDER - Confidential treatment order 171091195
  2. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 171077331
  3. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 171045719
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171021581
  5. 8-K - Current report 171021526
  6. 8-K - Current report 17966114
  7. 8-K - Current report 17925182
  8. 424B5 - Prospectus [Rule 424(b)(5)] 17925158
  9. 8-K - Current report 17918773
  10. 424B5 - Prospectus [Rule 424(b)(5)] 17918636